Categories: Market Research

Companion Animal Pharmaceuticals Market Growth, Share And Forecast To 2033

The companion animal pharmaceuticals global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Companion Animal Pharmaceuticals Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size –
The companion animal pharmaceuticals market size has grown strongly in recent years. It will grow from $15.23 billion in 2023 to $16.63 billion in 2024 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to humanization of pets, preventive healthcare measures, rise in pet insurance, changing lifestyle and urbanization, zoonotic disease concerns, zoonotic disease concerns, veterinary healthcare accessibility.

The companion animal pharmaceuticals market size is expected to see strong growth in the next few years. It will grow to $24.2 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to personalized medicine for pets, telehealth and remote veterinary services, focus on nutrition and nutraceuticals, one health initiatives, expansion of veterinary diagnostic services. Major trends in the forecast period include advancements in veterinary medicine, specialized therapeutics for aging pets, regulatory compliance and safety standards, collaborations and partnerships.

Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/companion-animal-pharmaceuticals-global-market-report

Scope Of Companion Animal Pharmaceuticals Market
The Business Research Company’s reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Companion Animal Pharmaceuticals Market Overview

Market Drivers –
The growing prevalence of zoonotic diseases is expected to propel the growth of the companion animal pharmaceuticals market going forward. A zoonotic illness is a disease that can be naturally transferred from vertebrate animals to humans or from people to vertebrate animals. The pharmaceutical industry is embracing modern tactics and strategies that are consistent with one set of health principles in order to combat zoonotic illnesses and lower the likelihood of transmission. For instance, in December 2022, according to a report published by the European Centre for Disease Prevention and Control, a Sweden-based government agency, Campylobacteriosis remains the most prevalent zoonosis, with a notable rise in reported cases to 127,840 in 2022. Chicken and turkey meat accounted for the majority of reported Campylobacteriosis cases. Salmonella, the second most common zoonosis, infected 60,050 individuals. Following Campylobacteriosis and Salmonellosis, Yersiniosis (6,789 cases), Shigatoxin-producing E. coli infections (6,084 cases), and Listeriosis (2,183 cases) were the most frequently reported zoonotic diseases. Therefore, the growing prevalence of zoonotic diseases is driving the growth of the companion animal pharmaceuticals market.

Market Trends –
Embracing big data technologies is a key trend gaining popularity in the companion animal pharmaceuticals. Major companies operating in the companion animal pharmaceuticals market are focused on developing new technological solutions to strengthen their position. For Instance, in April 2022, Elanco Animal Health Incorporated, a US-based company operating in companion animal pharmaceuticals, and Ginkgo Bioworks, a US-based company operating in companion animal pharmaceuticals launched BiomEdit, a microbiome innovation company for creating innovation in animal health. This will provide novel probiotics and other related animal pharmaceuticals for animal health innovation, such as medicated feed ingredients, nutritional health and therapies for livestock and pet animals, and biosecurity technologies for animal illness monitoring.

The companion animal pharmaceuticals market covered in this report is segmented –

1) By Animal Type: Dogs, Cats, Horses, Other Companion Animals
2) By Indication: Infectious Diseases, Dermatologic Diseases, Pain, Orthopedic Diseases, Behavioral Diseases, Other Indications
3) By Distribution Channels: Veterinary Hospitals, Veterinary Clinics, Retail Pharmacies

Get an inside scoop of the companion animal pharmaceuticals market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample_request?id=7983&type=smp

Regional Insights –
North America was the largest region in the companion animal pharmaceuticals market in 2023. Asia-Pacific is expected to be the fastest-growing region in the companion animal pharmaceuticals market report during the forecast period. The regions covered in the companion animal pharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies –
Major companies operating in the companion animal pharmaceuticals market report are Elanco Animal Health Incorporated, Boehringer Ingelheim International GmbH, Ceva Santé Animale, Chanelle Pharma, Eco Animal Health Group plc, Ashish Life Science Pvt. Ltd., Endovac Animal Health, Hipra Laboratories, Indian Immunologicals Ltd., Inovet Group, Kyoritsu Seiyaku Corporation, Lutim Pharma Pvt. Ltd., Merck & Co. Inc., Norbrook Laboratories Ltd., Tianjin Ringpu Bio-Technology Co. Ltd., Vetoquinol S.A., Virbac S.A., Zoetis Inc., Agrolabo S.p.A., ALS Pvt. Ltd., Zydus Animal Health and Investments Limited, Eli Lilly and Company, IDECompanion Animal Pharmaceuticals Market Laboratories Inc., Merial Limited, Novartis Animal Health Inc., Dechra Pharmaceuticals PLC, Aratana Therapeutics Inc., Phibro Animal Health Corporation, Kindred Biosciences Inc., Jaguar Health Inc., Nexvet Biopharma plc, Sentinel Biomedical Inc., PetMed Express Inc., Neogen Corporation, Heska Corporation, Synbiotics Corporation, Eurovet Animal Health B.V., Vironova AB, Abaxis Inc., Bioiberica S.A.U., Putney Inc., Lohmann Animal Health International

Table of Contents

1. Executive Summary

2. Companion Animal Pharmaceuticals Market Characteristics

3. Companion Animal Pharmaceuticals Market Trends And Strategies

4. Companion Animal Pharmaceuticals Market – Macro Economic Scenario

5. Global Companion Animal Pharmaceuticals Market Size and Growth

…..

32. Global Companion Animal Pharmaceuticals Market Competitive Benchmarking

33. Global Companion Animal Pharmaceuticals Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Companion Animal Pharmaceuticals Market

35. Companion Animal Pharmaceuticals Market Future Outlook and Potential Analysis

36. Appendix